Iridex Corporation Study Shows Sustained IOP Reduction with Laser Therapy for Glaucoma
What happened
Iridex Corporation announced the publication of a two-year clinical study demonstrating favorable outcomes using transscleral laser therapy (TLT) with MicroPulse® Technology. The retrospective study, led by Michele Lanza, evaluated 84 eyes of 53 patients with primary open-angle or primary angle-closure glaucoma. The results showed sustained IOP reduction and reduced medication burden over 24 months.
From manilatimes.net
Why it matters
The findings suggest that MicroPulse TLT may play a role earlier in the glaucoma treatment continuum than traditionally considered. This clinical validation supports the market position of Iridex Corporation's laser-based medical systems.
From manilatimes.net
Who's involved
- IridexDeveloped and utilized the MicroPulse® Technology and Cyclo G6® Laser in the study.
- Michele LanzaServed as the lead author of the clinical study.
- University of Campania "Luigi Vanvitelli"Affiliated with Michele Lanza, the lead author of the study.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- IridexSpeculative
Iridex Corporation might see increased sales or market position due to the clinical validation of its technology.
- University of Campania "Luigi Vanvitelli"Speculative
University of Campania "Luigi Vanvitelli" may see increased research funding or institutional investment.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Iridex
waste management company in Romania
Nothing else this week.